Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    - Added Revision: v3.5.2. - Deleted Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-17T14:15:27.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    Added revision: v3.5.0 and removed revision: v3.4.3 from the version history.
    Difference
    0.1%
    Check dated 2026-03-19T23:41:37.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Revision history updated: added v3.4.3 and removed v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-12T19:49:34.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    A new revision v3.4.2 was added to the study record history, replacing the previous v3.4.1. This update is a metadata-level change and does not alter substantive study data or results.
    Difference
    0.1%
    Check dated 2026-02-12T01:50:32.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    The record history now shows a new revision v3.4.1 added and the previous v3.4.0 removed, reflecting a minor update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T23:50:28.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The updates are limited to user interface elements (Show glossary, color-coded diffs) and metadata (revision labels), with the No FEAR Act data item removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.9%
    Check dated 2026-01-28T21:40:55.000Z thumbnail image

Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.